SG11202012133TA - Variant antibody that binds cd38 - Google Patents

Variant antibody that binds cd38

Info

Publication number
SG11202012133TA
SG11202012133TA SG11202012133TA SG11202012133TA SG11202012133TA SG 11202012133T A SG11202012133T A SG 11202012133TA SG 11202012133T A SG11202012133T A SG 11202012133TA SG 11202012133T A SG11202012133T A SG 11202012133TA SG 11202012133T A SG11202012133T A SG 11202012133TA
Authority
SG
Singapore
Prior art keywords
binds
variant antibody
antibody
variant
Prior art date
Application number
SG11202012133TA
Other languages
English (en)
Inventor
Barbara A Swanson
Heyue Zhou
Jian Cao
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of SG11202012133TA publication Critical patent/SG11202012133TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202012133TA 2018-06-20 2019-03-08 Variant antibody that binds cd38 SG11202012133TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687695P 2018-06-20 2018-06-20
PCT/US2019/021417 WO2019245616A1 (en) 2018-06-20 2019-03-08 Variant antibody that binds cd38

Publications (1)

Publication Number Publication Date
SG11202012133TA true SG11202012133TA (en) 2021-01-28

Family

ID=68984328

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012133TA SG11202012133TA (en) 2018-06-20 2019-03-08 Variant antibody that binds cd38

Country Status (10)

Country Link
US (1) US20210130484A1 (es)
EP (1) EP3810655A4 (es)
JP (2) JP2021528067A (es)
KR (1) KR20210022684A (es)
CN (1) CN112313250A (es)
AU (1) AU2019288972A1 (es)
CA (1) CA3103114A1 (es)
MX (1) MX2020014265A (es)
SG (1) SG11202012133TA (es)
WO (1) WO2019245616A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947465A4 (en) * 2019-03-29 2023-01-04 Sorrento Therapeutics, Inc. ANTIBODIES MANIPULATED VARIANTS BINDING TO CD38
TW202134280A (zh) 2019-12-05 2021-09-16 美商索倫多醫療公司 包含抗cd47抗體與腫瘤靶向抗體之組合物及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006301446B2 (en) * 2005-10-12 2012-06-07 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
AU2012212297B2 (en) * 2011-01-31 2016-03-17 Northwestern University Injectable thermoresponsive polyelectrolytes
US10085651B2 (en) * 2012-03-15 2018-10-02 The Penn State Research Foundation Methods for predicting and treating necrotizing enterocolitis in neonates
EP3280443B1 (en) * 2015-04-08 2022-08-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
WO2017072310A1 (en) * 2015-10-30 2017-05-04 Medimmune Limited Prevention of n-terminal truncation in igg light chains
CA3067311A1 (en) * 2017-06-20 2018-12-27 Sorrento Therapeutics, Inc. Cd38 antibody drug conjugate
KR20200076732A (ko) * 2017-11-03 2020-06-29 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38-지시된 키메라 항원 수용체 작제물
CA3092993A1 (en) * 2018-03-09 2019-09-12 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dar)
EP3947465A4 (en) * 2019-03-29 2023-01-04 Sorrento Therapeutics, Inc. ANTIBODIES MANIPULATED VARIANTS BINDING TO CD38

Also Published As

Publication number Publication date
AU2019288972A1 (en) 2021-02-04
US20210130484A1 (en) 2021-05-06
JP2024036508A (ja) 2024-03-15
EP3810655A4 (en) 2022-03-16
WO2019245616A9 (en) 2020-12-24
EP3810655A1 (en) 2021-04-28
CA3103114A1 (en) 2019-12-26
KR20210022684A (ko) 2021-03-03
CN112313250A (zh) 2021-02-02
WO2019245616A1 (en) 2019-12-26
MX2020014265A (es) 2021-05-27
JP2021528067A (ja) 2021-10-21

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-SIRPalpha antibody
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280780A (en) Anti-TIGIT antibodies
IL279352A (en) IL-11RA antibodies
IL283812B (en) Humanized antibody against human pd–1
IL280013A (en) Anti-IL36R antibodies
IL278010A (en) Antibodies to galectin 10
IL277030A (en) Antibodies
SG11202106171WA (en) Anti-btla antibodies
ZA202101177B (en) Anti-btla antibody
ZA202004908B (en) Bispecific antibody
GB201811368D0 (en) Antibody
IL281594A (en) Antibodies against KLRG1
ZA202108836B (en) Anti-epha4 antibody
GB201817172D0 (en) Antibody
GB201806084D0 (en) Antibodies
SG11202012133TA (en) Variant antibody that binds cd38
GB201911211D0 (en) Monoclonal antibodies against ambra-1
GB201820006D0 (en) Humanised anti-IL17BR antibody
GB201919062D0 (en) Antibody
GB201912008D0 (en) Antibody
SG11201913540VA (en) Anti-Podoplanin Antibody
GB201900983D0 (en) Antibody
GB201900724D0 (en) Antibody
GB201813597D0 (en) Antibody